The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Marley Spoon business combination with 468 SPAC II
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Syrah Resources
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Moorebank Intermodal Terminal
Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Trident Resources Corporation
Advised Chilton Investment Company on Trident’s financial restructuring and emergence from CCAA / Chapter 11 bankruptcy protection including the negotiation of a new equity investment